9.8% Average Loss With Semaglutide in HFpEF and Type 2 Diabetes
STEP-HFpEF DM found semaglutide improved weight and symptoms at 52 weeks in adults with obesity-related HFpEF and type 2 diabetes, with study limits.
At week 52, mean body-weight change was −9.8% with semaglutide and −3.4% with placebo; KCCQ clinical summary score change was +13.7 and +6.4 points, respectively.
616 adults with obesity-related HFpEF, a left-ventricular ejection fraction of at least 45%, and type 2 diabetes; 52-week treatment period; 57 weeks for the hierarchical composite follow-up. Read the linked peer-reviewed source for the full methodology, findings, and limitations.